Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Enzalutamide (DB08899)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03999515Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTreatment
NCT04116775Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.Treatment
NCT0281496818F-FDG PET/CT and Whole Body MRI for Staging and Response Prediction in Castration-resistant Prostate Cancer Patients Receiving EnzalutamideTreatment